<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04850378</url>
  </required_header>
  <id_info>
    <org_study_id>Prot-0824-2019</org_study_id>
    <nct_id>NCT04850378</nct_id>
  </id_info>
  <brief_title>Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome</brief_title>
  <acronym>CAPTAIN</acronym>
  <official_title>Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to describe the biochemical coagulation profile and investigate the effect of&#xD;
      Low molecular weight heparin and Apixaban on this profile in patients with nephrotic&#xD;
      syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The initial part of the study is a prospective cross-sectional study which will describe the&#xD;
      biochemical coagulation profile in nephrotic patients. It will include 60 patients with&#xD;
      nephrotic syndrome and data from 50 anonymous blood donors matched in age and gender for&#xD;
      comparison.&#xD;
&#xD;
      The second part of the study is an open-label, controlled, non-randomized, interventional&#xD;
      clinical trial consisting of 3 groups of patients with nephrotic syndrome or atrial&#xD;
      fibrillation treated with either Dalteparin or Apixaban. The study participant is expected to&#xD;
      be in stable condition after 4 full days of treatment. For administrative reasons, the final&#xD;
      biochemical tests are performed on day 4, 5, 6 or 7 described as day 4 in this protocol.&#xD;
&#xD;
        -  Group A: Up to 50 patients with nephrotic syndrome treated with injection Dalteparin 200&#xD;
           Units/kg subcutaneous once a day for 4 days&#xD;
&#xD;
        -  Group B: 10 patients with nephrotic syndrome and membranous nephropathy treated with&#xD;
           Apixaban 5 mg twice daily for 4 days.&#xD;
&#xD;
        -  Group C: 10 patients with atrial fibrillation and no kidney disease treated with&#xD;
           Apixaban 5 mg twice daily for 4 days.&#xD;
&#xD;
      Patients participating in the initial part of the study will be included in det second part&#xD;
      (Group A) if they meet the inclusion criteria. If the patient is diagnosed with membranous&#xD;
      nephropathy it is possible to be included in the initial part as well as the second part&#xD;
      (Group A and B).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>An open-label, controlled, non-randomized, interventional clinical trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Initial Thrombin Generation Assay in nephrotic patients treated with Dalteparin</measure>
    <time_frame>Predose on Day 1</time_frame>
    <description>Thrombin Generation Assay is used to monitor the anticoagulation therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady state Thrombin Generation Assay (TGA) in nephrotic patients treated with Dalteparin (Nadir TGA value)</measure>
    <time_frame>Predose day 4</time_frame>
    <description>Thrombin Generation Assay is used to monitor the anticoagulation therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady state Thrombin Generation Assay (TGA) in nephrotic patients treated with Dalteparin (4 hours TGA value)</measure>
    <time_frame>4 hours postdose on Day 4</time_frame>
    <description>Thrombin Generation Assay is used to monitor the anticoagulation therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Initial Thrombin Generation Assay in nephrotic patients treated with Apixaban</measure>
    <time_frame>Predose on Day 1</time_frame>
    <description>Thrombin Generation Assay is used to monitor the anticoagulation therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Thrombin Generation Assay in nephrotic patients treated with Apixaban over the first 24 hours.</measure>
    <time_frame>24 hours</time_frame>
    <description>Thrombin Generation Assay is used to monitor the anticoagulation therapy with blood samples at 2.5, 8, 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady state Thrombin Generation Assay in nephrotic patients treated with Apixaban.</measure>
    <time_frame>Predose day 4</time_frame>
    <description>Thrombin Generation Assay is used to monitor the anticoagulation therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Initial Thrombin Generation Assay in patients with atrial fibrillation and no kidney disease treated with Apixaban</measure>
    <time_frame>Predose on Day 1</time_frame>
    <description>Thrombin Generation Assay is used to monitor the anticoagulation therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Thrombin Generation Assay in patients with atrial fibrillation and no kidney disease treated with Apixaban over the first 24 hours.</measure>
    <time_frame>24 hours</time_frame>
    <description>Thrombin Generation Assay is used to monitor the anticoagulation therapy with blood samples at 2.5, 8, 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady state Thrombin Generation Assay in patients with atrial fibrillation and no kidney disease treated with Apixaban.</measure>
    <time_frame>Predose day 4</time_frame>
    <description>Thrombin Generation Assay is used to monitor the anticoagulation therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparing Thrombin Generation Assay between group B and C.</measure>
    <time_frame>Predose, 2.5, 8, 24 hours and predose Day 4</time_frame>
    <description>Comparing Thrombin Generation Assay in nephrotic patients treated with Apixaban and patients with atrial fibrillation treated with Apixaban.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparing Thrombin Generation Assay between group A and C.</measure>
    <time_frame>Baseline and predose Day 4</time_frame>
    <description>Comparing Thrombin Generation Assay in nephrotic patients treated with Dalteparin and patients with atrial fibrillation treated with Apixaban.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparing Thrombin Generation Assay between group A and B.</measure>
    <time_frame>Baseline and predose Day 4</time_frame>
    <description>Comparing Thrombin Generation Assay in nephrotic patients treated with Dalteparin and nephrotic patients treated with Apixaban.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of bleeding-events durin the study.</measure>
    <time_frame>Predose until 7 days after last dose of apixaban.</time_frame>
    <description>Number of cases with bleeding-events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of thromboembolic complications during the study.</measure>
    <time_frame>Predose until 7 days after last dose of apixaban.</time_frame>
    <description>Number of cases with thromboembolic complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparing plasma concentration of Apixaban between group B and C</measure>
    <time_frame>Day 4</time_frame>
    <description>Comparing plasma-Apixaban in nephrotic patients and patients with atrial fibrillation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparing urine concentration of Apixaban between group B and C</measure>
    <time_frame>Day 4</time_frame>
    <description>Comparing urine-Apixaban in nephrotic patients and patients with atrial fibrillation.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Nephrotic Syndrome</condition>
  <condition>Thromboembolic Disease</condition>
  <arm_group>
    <arm_group_label>Coagulation profile in Nephrotic syndrome</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Investigation of the biochemical coagulation profile in patients with nephrotic syndrome.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nephrotic syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nephrotic patients without diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Membranous nephropathy and nephrotic syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Membranous nephropathy and nephrotic syndrome.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atrial fibrillation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atrial fibrillation with no kidney disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalteparin</intervention_name>
    <description>Drug: Dalteparin 200 units/kg once a day for 4-7 days.</description>
    <arm_group_label>Nephrotic syndrome</arm_group_label>
    <other_name>Fragmin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Drug: Apixaban 5 mg twice a day for 4-7 days.</description>
    <arm_group_label>Atrial fibrillation</arm_group_label>
    <arm_group_label>Membranous nephropathy and nephrotic syndrome</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Nephrotic patients - no intervention&#xD;
&#xD;
          -  Age 18-79 years&#xD;
&#xD;
          -  Estimated Glomerular Filtration Rate (eGFR) &gt; 49 mL/min/1.73 m2&#xD;
&#xD;
          -  P-albumin &lt; 30 g/L&#xD;
&#xD;
          -  U-Albumin excretion &gt; 2.2 g/day&#xD;
&#xD;
          -  Known glomerular disease including membranous nephropathy, which may cause nephrotic&#xD;
             syndrome or diagnostically unresolved nephrotic syndrome with a planed kidney biopsy.&#xD;
&#xD;
        Inclusion Criteria: Nephrotic patients treated with Dalteparin&#xD;
&#xD;
          -  Age 18-79 years&#xD;
&#xD;
          -  eGFR &gt; 49 mL/min/1.73 m2&#xD;
&#xD;
          -  P-albumin &lt; 25 g/L&#xD;
&#xD;
          -  U-Albumin excretion &gt; 2.2 g/day&#xD;
&#xD;
          -  Known glomerular disease including membranous nephropathy, which may cause nephrotic&#xD;
             syndrome or diagnostically unresolved nephrotic syndrome with a planed kidney biopsy.&#xD;
&#xD;
        Inclusion Criteria: Nephrotic patients treated with Apixaban&#xD;
&#xD;
          -  Age 18-79 years&#xD;
&#xD;
          -  eGFR &gt; 49 mL/min/1.73 m2&#xD;
&#xD;
          -  P-albumin &lt; 25 g/L&#xD;
&#xD;
          -  U-Albumin excretion &gt; 2.2 g/day&#xD;
&#xD;
          -  Membranous Nephropathy&#xD;
&#xD;
        Inclusion Criteria: Patients with atrial fibrillation treated with Apixaban&#xD;
&#xD;
          -  Age 18-79 years&#xD;
&#xD;
          -  eGFR &gt; 49 mL/min/1.73 m2&#xD;
&#xD;
          -  P-albumin &gt; 36 g/L&#xD;
&#xD;
          -  U-Albumin excretion &lt; 300 mg/day&#xD;
&#xD;
          -  Atrial Fibrillation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to Apixaban&#xD;
&#xD;
          -  Contraindication to Dalteparin&#xD;
&#xD;
          -  Known allergy or intolerance to Apixaban&#xD;
&#xD;
          -  Known allergy or intolerance to Dalteparin&#xD;
&#xD;
          -  Treatment with anticoagulation for other reasons.&#xD;
&#xD;
          -  Treatment with cyclooxygenase-1-inhibitors or Adenosine Diphosphate (ADP) receptor&#xD;
             inhibitors.&#xD;
&#xD;
          -  Known acquired or congenital coagulation defect non related to nephrotic syndrome or&#xD;
             thromboembolic disease within 3 months.&#xD;
&#xD;
          -  Known diabetes mellitus.&#xD;
&#xD;
          -  Lack of compliance, comorbidity or other conditions that, in the patients unfit to&#xD;
             participate in the trial.&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Kelddal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Kelddal, MD</last_name>
    <phone>+45 4046 0803</phone>
    <email>sarah.kelddal@midt.rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Henrik Birn, Professor</last_name>
    <phone>+45 4046 0271</phone>
    <email>hb@biomed.au.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Kelddal, MD</last_name>
      <phone>+45 4046 0803</phone>
      <email>sarah.kelddal@midt.rm.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2021</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nephrotic Syndrome</keyword>
  <keyword>Glomerulonephritis</keyword>
  <keyword>Hypoalbuminemia</keyword>
  <keyword>Proteinuria</keyword>
  <keyword>Thromboembolic Disease</keyword>
  <keyword>Membranous Nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

